Cardiovascular Systems (CSII) Given News Sentiment Score of 0.07

News stories about Cardiovascular Systems (NASDAQ:CSII) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cardiovascular Systems earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.0698500037918 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of NASDAQ CSII opened at $22.87 on Friday. Cardiovascular Systems has a 1 year low of $20.58 and a 1 year high of $33.11. The firm has a market cap of $770.66, a P/E ratio of 762.33 and a beta of 2.15. The company has a current ratio of 4.65, a quick ratio of 4.13 and a debt-to-equity ratio of 0.17.

How to Become a New Pot Stock Millionaire

Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.50%. The firm had revenue of $52.63 million for the quarter, compared to the consensus estimate of $53.39 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. research analysts anticipate that Cardiovascular Systems will post -0.07 EPS for the current year.

CSII has been the topic of a number of recent analyst reports. Needham & Company LLC downgraded shares of Cardiovascular Systems from a “buy” rating to a “hold” rating and lowered their price target for the stock from $33.11 to $23.00 in a report on Friday, December 15th. William Blair reissued a “market perform” rating on shares of Cardiovascular Systems in a report on Thursday, December 21st. BidaskClub downgraded shares of Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 27th. ValuEngine downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Leerink Swann lowered their price target on shares of Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. Cardiovascular Systems has a consensus rating of “Hold” and a consensus price target of $27.00.

ILLEGAL ACTIVITY NOTICE: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3338197/cardiovascular-systems-csii-given-news-sentiment-score-of-0-07.html.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Financial Review: Carvana  versus Its Competitors
Financial Review: Carvana versus Its Competitors
Brokerages Set Callon Petroleum  PT at $16.42
Brokerages Set Callon Petroleum PT at $16.42
Analyzing Paychex  and Forrester Research
Analyzing Paychex and Forrester Research
Head to Head Contrast: Aspen Group  versus The Competition
Head to Head Contrast: Aspen Group versus The Competition
Contrasting Rogers  & AdvanSix
Contrasting Rogers & AdvanSix
SSLJ.Com  Downgraded by ValuEngine
SSLJ.Com Downgraded by ValuEngine


Leave a Reply

© 2006-2018 Ticker Report. Google+.